MD1003(高剂量生物素)治疗进展型多发性硬化的安全性及有效性:SPI2随机双盲安慰剂对照3期试验
SPI2是一项在13国90个中心开展的随机双盲安慰剂对照3期试验,纳入642例进展型多发性硬化患者,评估口服MD1003(生物素100 mg每日三次)的疗效与安全性。两组治疗中出现的不良事件发生率相似,但MD1003可导致基于生物素化抗体的实验室检测结果不准确。
要点
- MD1003未显著改善进展型多发性硬化患者的残疾或步行速度。
- MD1003可干扰基于生物素化抗体的实验室检测,导致结果不准确。
- 基于无效及潜在实验室干扰风险,不推荐MD1003用于进展型多发性硬化。
核心结论
- MD1003未能显著改善进展型多发性硬化患者的残疾或步行速度,且可导致实验室检测结果不准确,因此不推荐用于治疗进展型多发性硬化。
研究设计与样本
- SPI2为随机、双盲、平行组、安慰剂对照3期试验,在13个国家90个学术及社区多发性硬化诊所开展。
- 642例参与者按1:1随机分配至MD1003(口服生物素100 mg每日三次,n=326)或安慰剂(n=316),按研究中心和疾病史分层。
- 主要终点为12个月时EDSS或TW25确认改善(15个月确认)的复合比例,在意向治疗集分析。
主要发现
- 治疗中出现的不良事件:MD1003组277/331(84%)对比安慰剂组264/311(85%)。
- 严重治疗中出现的不良事件:MD1003组87/331(26%)对比安慰剂组82/311(26%)。
- 死亡:MD1003组1例(<1%),安慰剂组0例。
- MD1003导致基于生物素化抗体的实验室检测结果不准确。
临床怎么用
- 不应将MD1003用于进展型多发性硬化的治疗。
- 使用MD1003的患者需警惕基于生物素化抗体的实验室检测结果不准确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is an unmet need to develop therapeutic interventions directed at the neurodegeneration that underlies progression in multiple sclerosis. High-dose, pharmaceutical-grade biotin (MD1003) might enhance neuronal and oligodendrocyte energetics, resulting in improved cell function, repair, or survival. The MS-SPI randomised, double-blind, placebo-controlled study found that MD1003 improved disability outcomes over 12 months in patients with progressive multiple sclerosis. The SPI2 study was designed to assess the safety and efficacy of MD1003 in progressive forms of multiple sclerosis in a larger, more representative patient cohort. METHODS: SPI2 was a randomised, double-blind, parallel-group, placebo-controlled trial done at 90 academic and community multiple sclerosis clinics across 13 countries. Patients were aged 18-65 years, had a diagnosis of primary or secondary progressive multiple sclerosis fulfilling the revised International Panel criteria and Lublin criteria, a Kurtzke pyramidal functional subscore of at least 2 (defined as minimal disability), an expanded disability status scale (EDSS) score of 3·5-6·5, a timed 25-foot walk (TW25) of less than 40 s, evidence of clinical disability progression, and no relapses in the 2 years before enrolment. Concomitant disease-modifying therapies were allowed. Patients were randomly assigned (1:1) by an independent statistician using an interactive web response system, with stratification by study site and disease history, to receive MD1003 (oral biotin 100 mg three times daily) or placebo. Participants, investigators, and assessors were masked to treatment assignment. The primary endpoint was a composite of the proportion of participants with confirmed improvement in EDSS or TW25 at month 12, confirmed at month 15, versus baseline. The primary endpoint was assessed in the intention-to-treat analysis set, after all participants completed the month 15 visit. Safety analyses included all participants who received at least one dose of MD1003. This trial is registered with ClinicalTrials.gov (NCT02936037) and the EudraCT database (2016-000700-29). FINDINGS: From Feb 22, 2017, to June 8, 2018, 642 participants were randomly assigned MD1003 (n=326) or placebo (n=316). The double-blind, placebo-controlled phase of the study ended when the primary endpoint for the last-entered participant was assessed on Nov 15, 2019. The mean time in the placebo-controlled phase was 20·1 months (SD 5·3; range 15-27). For the primary outcome, 39 (12%) of 326 patients in the MD1003 group compared with 29 (9%) of 316 in the placebo group improved at month 12, with confirmation at month 15 (odds ratio 1·35 [95% CI 0·81-2·26]). Treatment-emergent adverse events occurred in 277 (84%) of 331 participants in the MD1003 group and in 264 (85%) of 311 in the placebo group. 87 (26%) of 331 participants in the MD1003 group and 82 (26%) of 311 participants in the placebo group had at least one serious treatment-emergent adverse event. One (<1%) person died in the MD1003 group and there were no deaths in the placebo group. Despite use of mitigation strategies, MD1003 led to inaccurate laboratory results for tests using biotinylated antibodies. INTERPRETATION: This study showed that MD1003 did not significantly improve disability or walking speed in patients with progressive multiple sclerosis and thus, in addition to the potential of MD1003 for deleterious health consequences from interference of laboratory tests, MD1003 cannot be recommended for treatment of progressive multiple sclerosis. FUNDING: MedDay Pharmaceuticals.
引用
- Cree BAC, Cutter G, Wolinsky JS, et al. Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2020. PMID: 33222767. doi:10.1016/S1474-4422(20)30347-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。